About Us
Author Guidelines
Contact Us
Supplier Info
 


Current Issue
Sample issue of JATCurrent Issue


Contact Info:
6600 W. Touhy Ave.
Niles, IL 60714
Tel: 847.647.2900
Fax: 847.647.1155
circulation@jatox.com

 

 
   

Journal of Analytical Toxicology Article Abstracts

Journal of Analytical Toxicology Horizontal Line

Published: Journal of Analytical Toxicology, ISSN 0146-4760, Volume 26, Number 7, October 2002, pp. 448-459

Oxycontin®: The Concept of a “Ghost Pill” and the Postmortem Tissue Distribution of Oxycodone in 36 Cases
Daniel T. Anderson, Kristina L. Fritz, and Joseph J. Muto
Los Angeles County Department of Coroner, 1104 N. Mission Road, Los Angeles, California 90033

Oxycodone is a semi-synthetic opioid that is structurally similar to codeine and equipotent to morphine in producing analgesic effects. Oxycodone has been prescribed in many immediate-release formulations including Percodan®, Percocet®, Tylox®, Roxicodone®, and Toxicet®. In 1995, the Food and Drug Administration approved Oxycontin, a controlled-release form of oxycodone. Although the immediate-release forms of oxycodone can be prescribed in doses of 10–30 mg every 4 h, it is recommended that Oxycontin be prescribed in doses of 10–160 mg every 12 h. In a six-year period, the Los Angeles County Department of Coroner’s Toxicology Laboratory detected oxycodone in 67 cases, 36 of which were determined to be the controlled-release form. The objectives of this paper are to provide general information about Oxycontin, including postmortem tissue distributions of oxycodone in cases in which the controlled-release form was identified, and to introduce the concept of ghost pills. A ghost pill is a seemingly intact but drug-free tablet that resembles an undigested pill. The isolation and identification of oxycodone from postmortem specimens was achieved using a basic, liquid–liquid extraction with screening and quantitation by gas chromatography–nitrogen-phosphorus detection and gas chromatography–mass spectrometry, respectively. Oxycodone-d3 was used as an internal standard for quantitation. The assays were linear from 0.10 to 5.0 mg/L. The tissue distribution ranges of oxycodone in the 36 case examples were heart blood 0.12–46 mg/L (36), femoral blood +<0.10–13 mg/L (35), liver 0.11–6.1 mg/kg (16), urine 2.5–122 mg/L (22), bile 0.19–49 mg/L (15), vitreous 0.24–0.82 mg/L (6), and gastric 0.06–119 mg total (21).

Reproduction of editorial content of this journal is prohibited without publisher’s permission.

This article is available in its entirety by fax for $40.00 each.
Visa, MasterCard and AMEX accepted.

To order electronically click here
or call: 847-647-2900 ext. 1323
or fax request to: 847-647-1155.

To order multiple copies click here.

Please indicate JAT volume and issue along with page numbers.


| Home | Subscribe | Current Issue | Back Issues | Search | Advertise | Other Publications |